Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

Information for patients

The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.

 

Astellas
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

The challenge

  • Understanding anaemia of CKD

    Anaemia is a common feature of chronic kidney disease,1 and one of the hallmarks of advanced CKD.2,3

    The prevalence of anaemia increases as CKD progresses, from 42.5% at stage 3b CKD to 83.7% in people with stage 5 CKD.4

    Anaemia is known to be caused by a number of factors, including:1,6-9

    Illustration of kidneys

    Disrupted oxygen sensing in the kidney

    Illustration of red blood cells

    Reduced erythropoietin production

    Illustration of liver

    Chronic inflammation resulting in increased hepcidin levels

    Illustration of blood droplet with arrow

    Iron deficiency

    1_1_HIF mechanism_GIF_CKD

    Inverse relationship between Hepcidin (Hep) and available iron (Fe) and plasma Erythropoetin (EPO) concentration. With inflammation and Hep production red blood cell (RBC) production and Hb decreases.

    As CKD progresses:5
    • EPO production decreases, leading to a reduction in red blood cells and haemoglobin
    • Hepcidin levels are elevated due to inflammation and decreased renal excretion
    • Elevated hepcidin leads to a reduction in absorption, recycling and mobilisation of iron

    CKD, chronic kidney disease; EPO, erythropoietin.

    References

    • Babitt JL, Lin HY. J Am Soc Nephrol. 2012;(10)23:1631-1634.
    • Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.
    • Koury MJ, Haase VH. Nat Rev Nephrol. 2015;11:394–410.
    • Evans M et al. Clin Kidney J. 2020;13(5):821-827.
    • Locatelli F et al. Am J Nephrol. 2017;45:187-199.
    • Wenger RH, Hoogewijs D. Am J Physiol Renal Physiol. 2010;298:F1287–F1296.
    • Fishbane S, Spinowitz B. Am J Kidney Dis. 2018;71:423–435.
    • Peyssonnaux C et al. Cell Cycle. 2008;7:28–32.
    • Kaplan JM et al. Int J Mol Sci. 2018;19:389.

  • Treatment challenges

    A specialist's view

    The burden of anaemia of CKD and challenges in its management

    What do patients want from their treatment?

    Management of anaemia of CKD can be sub-optimal.1-3

    Treatment of anaemia of CKD is based on iron supplements and ESAs (erythropoiesis-stimulating agents).1

    These treatments target individual factors of anaemia of CKD.

    CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent.

    References

    • Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(7):613-621.
    • Guedes M et al. Kidney360. 2020;(1):855-62.
    • Lopes MB et al. Nature Scientific Reports. 2021;11:1784.

  • The need for an alternative treatment option

    Limitations of current therapies have driven a search for alternative treatment options.1

    Advances in the study of CKD-associated anaemia have focused on the pathophysiology of anaemia with the hope of discovering more targeted and physiological therapies.1-4

    The discovery of hypoxia-inducible factors (HIFs) has led to the development of a class of drugs that stimulate erythropoiesis by activating the HIF pathway.1,4,5

    Discover the HIF pathway

    CKD, chronic kidney disease; HIF, hypoxia-inducible factor.

    References

    • Locatelli F et al. Am J Nephrol. 2017;45:187-199.
    • Babitt JL, Lin HY. J Am Soc Nephrol. 2012;(10)23:1631-1634.
    • Koury MJ, Haase VH. Nat Rev Nephrol. 2015;11:394–410.
    • Haase VH. Hemodial Int. 2017;21:S110–S124.
    • Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(7):613-621.



EVRENZO™ (roxadustat), 20, 50, 70, 100 och 150 mg filmdragerade tabletter, B03XA05, Rx (särskilt läkemedel), F

▼Detta läkemedel är föremål för utökad övervakning.

Indikationen är behandling av vuxna patienter med symtomatisk anemi associerad med kronisk njursjukdom (CKD). Kontraindikationer är överkänslighet mot den aktiva substansen, jordnötter, soja eller hjälpämne, användning under graviditetens tredje trimester samt amning. Varningar och försiktighet inkluderar risk för allvarliga (inklusive dödliga) kardiovaskulära och trombovaskulära händelser, krampanfall och allvarliga infektioner inklusive sepsis. Ska inte sättas in hos kvinnor som planerar att bli gravida eller under graviditet. Fertila kvinnor måste använda en högeffektiv preventivmetod under behandling och i minst en vecka efter sista dosen. Försiktighet gällande administrering krävs vid måttligt nedsatt leverfunktion och rekommenderas inte vid kraftigt nedsatt leverfunktion. Felanvändning kan leda till en överdrivet förhöjd hematokrit vilket kan leda till livshotande komplikationer i hjärt-kärlsystemet.

Astellas Pharma AB, Box 21046, 200 21 Malmö. Produktresumé 2024-09. 

För ytterligare information och förpackningar se www.fass.se.